Lantheus (NASDAQ:LNTH) Announces Quarterly Earnings Results, Misses Estimates By $0.23 EPS

Lantheus (NASDAQ:LNTH) posted its earnings results on Thursday. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23), Zacks reports. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million.

Lantheus Stock Performance

Shares of LNTH opened at $93.82 on Friday. Lantheus has a fifty-two week low of $56.44 and a fifty-two week high of $126.89. The stock has a fifty day moving average of $89.80 and a two-hundred day moving average of $96.75. The company has a market capitalization of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44.

Insider Activity

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on LNTH. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Truist Financial increased their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.